Targeting the GBA1 gene offers a path to personalised treatment for Parkinson's

New research into the GBA1 gene is changing how we understand the progression of Parkinson's and, more importantly, how we might stop it. While we often speak about Parkinson's as one condition, it is actually quite varied. GBA1 mutations are now known as the most common genetic risk factor, appearing in about 15% of people with the condition. Even though many people carry these genetic variants without ever developing a synucleinopathy, for those who do, the GBA1 gene provides a clear target for new, precision therapies. The role of the GBA1 gene is to provide instructions for making an enzyme that acts like a waste disposal unit within our cells. This enzyme normally breaks down fatty substances to keep cells healthy. When the gene has a variant, the enzyme doesn’t work effectively, leading to a buildup of waste. This internal clutter makes it much easier for toxic proteins like alpha-synuclein to clump together, which is a key driver of the condition. Research shows that the specific type of GBA1 variant a person carries can influence their journey. People with more severe variants may experience a faster rate of progression, particularly regarding memory, thinking, and autonomic functions like blood pressure or digestion. By studying these mechanisms, scientists are creating "biomarker profiles"—essentially biological roadmaps—that help clinicians predict how the condition will behave in each individual. This deeper understanding has turned GBA1 into a major focus for drug development. Instead of just treating the symptoms, scientists are testing ways to fix the biological glitch itself. Some are working on "pharmacological chaperones" that help the faulty enzymes get to where they are needed, while others are developing "activators" to boost enzyme performance. There are even trials looking at gene expression to see if we can dial up the body’s natural ability to clear out these toxic proteins. The most promising aspect of this work is that these treatments might not only help those with the GBA1 variant. Because the same waste-clearing system is often sluggish in all forms of Parkinson's, these new therapies could eventually benefit everyone with the condition. By moving away from a one-size-fits-all approach, we are entering an era of personalised medicine where treatments are built to match the specific biology of the person they are helping.